
Crinetics Pharmaceuticals Investor Relations Material
Latest events

R&D Day 2025
Crinetics Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Crinetics Pharmaceuticals Inc
Access all reports
Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company that specializes in the development of novel therapeutics targeting peptide hormone receptors. Their focus is on the treatment of rare endocrine disorders and endocrine-related tumors. The company’s leading product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist. It is in advanced clinical trials for conditions such as acromegaly, carcinoid syndrome, and nonfunctional neuroendocrine tumors. Additionally, Crinetics Pharmaceuticals is developing other drug candidates for conditions like congenital hyperinsulinism and Cushing's disease. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Key slides for Crinetics Pharmaceuticals Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Crinetics Pharmaceuticals Inc


43rd Annual J.P. Morgan Healthcare Conference 2025
Crinetics Pharmaceuticals Inc
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
CRNX
Country
🇺🇸 United States